Moderna, Inc. — Director's Dealing 2022

Nov 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-11-04

Reporting Person: Burton Paul (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-04	Common Stock	M	402	—	Acquired	1146	Direct
2022-11-07	Common Stock	S	192	$158.6817	Disposed	954	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-04	Restricted Stock Units	$0	M	402	Disposed		Common Stock (402)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans
to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3: 25% of the shares subject to this restricted stock unit award vested on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.